Table 1 Baseline characteristics
Characteristics | IPDMA | Van Vliet | Salim | |||
|---|---|---|---|---|---|---|
Nifedipine (n = 324) | Atosiban (n = 326) | Nifedipine (n = 249) | Atosiban (n = 256) | Nifedipine (n = 75) | Atosiban (n = 70) | |
Age (years) | 30.1 (26.0–34.0) | 30.0 (26.6–33.0) | 30.7 (26.2–34.1) | 30.2 (27.1–33.1) | 27.0 (25.0–33.0) | 28.0 (25.0–32.3) |
BMI (kg/m2) a | 22.7 (20.4–25.6) | 22.8 (20.4–25.5) | 23.1 (20.8–25.8) | 22.8 (20.5–25.6) | 21.4 (19.9–25.0) | 22.6 (20.2–25.3) |
Nulliparous | 197/323 (61) | 195/325 (60) | 160/248 (65) | 170/255 (67) | 37 (49) | 25 (36) |
Multiple pregnancy b | ||||||
 - Twin | 72 (22) | 58 (18) | 49 (20) | 37 (15) | 23 (31) | 21 (30) |
 - Triplet | 0 | 1 (0.3) | 0 | 1 (0.4) | 0 | 0 |
Previous preterm birth | 45/323 (14) | 45/324 (14) | 33/248 (13) | 30/254 (12) | 12 (16) | 15 (21) |
Gestational age at study entry (weeks) b | 31.1 (29.0–33.0) | 30.8 (28.9–32.6) | 30.9 (28.7–32.9) | 30.7 (28.6–32.4) | 31.9 (30.0–33.1) | 31.1 (29.7–32.8) |
PPROM at study entry b | 85 (26) | 88 (27) | 85 (34) | 88 (34) | 0 | 0 |
Vaginal examination at study entry | ||||||
 - Dilatation (cm) c | 1.0 (1.0–2.0) | 1.5 (1.0–2.0) | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 1.5 (1.0–2.0) | 1.5 (1.0–2.0) |
 - Effacement (%) d | 75 (50–100) | 75 (50–100) | 75 (50–100) | 75 (50–100) | 75 (50–75) | 75 (50–75) |